These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 18581695)

  • 1. Well-being, sleep, exercise patterns, and the menstrual cycle: a comparison of natural hormones, oral contraceptives and depo-provera.
    Brown SG; Morrison LA; Larkspur LM; Marsh AL; Nicolaisen N
    Women Health; 2008; 47(1):105-21. PubMed ID: 18581695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective study of adolescents who choose among levonorgestrel implant (Norplant), medroxyprogesterone acetate (Depo-Provera), or the combined oral contraceptive pill as contraception.
    Cromer BA; Smith RD; Blair JM; Dwyer J; Brown RT
    Pediatrics; 1994 Nov; 94(5):687-94. PubMed ID: 7936897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depo-provera: clinical evaluation.
    Mukherjea M
    Contracept Deliv Syst; 1981 Jul; 2(3):259-69. PubMed ID: 12278913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depo-Provera in adolescents: effects of early second injection or prior oral contraception.
    Harel Z; Biro FM; Kollar LM
    J Adolesc Health; 1995 May; 16(5):379-84. PubMed ID: 7662688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative acceptability of combined and progestin-only injectable contraceptives in Kenya.
    Ruminjo JK; Sekadde-Kigondu CB; Karanja JG; Rivera R; Nasution M; Nutley T
    Contraception; 2005 Aug; 72(2):138-45. PubMed ID: 16022854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and acceptability of depo-medroxyprogesterone acetate injection. As a method of contraception in Saudi Arabia.
    Sobande AA; Al-Bar HM; Archibong EI; Sadek AA
    Saudi Med J; 2000 Apr; 21(4):348-51. PubMed ID: 11533816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depo-Provera use in an Australian metropolitan practice.
    Fraser IS; Dennerstein GJ
    Med J Aust; 1994 May; 160(9):553-6. PubMed ID: 8164553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term contraception with Depo-Provera: a clinical evaluation.
    Mukherjea M; Mukherjee P; Biswas R
    Int J Fertil; 1980; 25(2):122-6. PubMed ID: 6117526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Contraception with Depo-Provera. Report of a series of 930 women].
    Mahjoub S; Lebbi I; Dakhli R; Smaïli L; Ben Hmjd R; Ben Romdhane M; Zouari F; Hamzaoui R
    Tunis Med; 2000 Nov; 78(11):662-6. PubMed ID: 11155390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adolescents' reasons for and experience after discontinuation of the long-acting contraceptives Depo-Provera and Norplant.
    Harel Z; Biro FM; Kollar LM; Rauh JL
    J Adolesc Health; 1996 Aug; 19(2):118-23. PubMed ID: 8863083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA gives final approval to Depo amid concerns over safety, cost and coercion.
    Wash Memo Alan Guttmacher Inst; 1992 Nov; (17):2-3. PubMed ID: 12344620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What is breast cancer risk with Depo-Provera?
    Contracept Technol Update; 1992 Jan; 13(1):15-6. PubMed ID: 12343459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adolescent knowledge and use of injectable contraceptives in developing countries.
    Singh S
    J Adolesc Health; 1995 May; 16(5):396-404. PubMed ID: 7662691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depo-Provera highly effective as injectable contraceptive.
    Denniston GC
    Contracept Technol Update; 1985 Dec; 6(12):167-8. PubMed ID: 12280301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of hormonal contraceptives in an institutional setting: reasons for use, consent and safety in women with psychiatric and intellectual disabilities.
    Egan TM; Siegert RJ; Fairley NA
    N Z Med J; 1993 Aug; 106(961):338-41. PubMed ID: 8341476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA board investigates Depo-Provera safety.
    Contracept Technol Update; 1983 Mar; 4(3):25-7. PubMed ID: 12266161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depo-Provera use in Sri Lanka: acceptor characteristics, continuation and side effects.
    Basnayake S; Thapa S
    Adv Contracept Deliv Syst; 1986 Oct; 2(4):307-21. PubMed ID: 12341188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depo-Provera: costs eat up clinic contraceptive budgets.
    Contracept Technol Update; 1999 Jan; 20(1):1-3. PubMed ID: 12349019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Injectable contraception.
    International Planned Parenthood Federation IPPF. International Medical Advisory Panel IMAP
    IPPF Med Bull; 1980 Dec; 14(6):1-3. PubMed ID: 12310087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.